Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Revenues	$ 118,192	$ 102,428	$ 84,452
Operating expenses:
Research and development	180,647	145,922	114,866
General and administrative	67,097	61,686	46,736
Total operating expenses	247,744	207,608	161,602
Loss from operations	(129,552)	(105,180)	(77,150)
Interest and other income, net	8,775	9,761	8,261
Loss before income taxes	(120,777)	(95,419)	(68,889)
Income tax expense	(345)	0	0
Net loss	(121,122)	(95,419)	(68,889)
Net loss attributable to non-controlling interest	(126)	(233)	(555)
Net loss attributable to Sangamo Therapeutics, Inc. stockholders	$ (120,996)	$ (95,186)	$ (68,334)
Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share)	$ (0.90)	$ (0.85)	$ (0.70)
Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares)	134,449	112,114	96,941